Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

760 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2024-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30 to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

NCT03570294

Premature Birth

COMPLETED NA

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

NCT00404768

Obstetric Labour, Premature

COMPLETED PHASE2

Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)

NCT06537778

Cervical Cerclage Premature Birth

COMPLETED NA

Effectiveness of ACS in Extreme Preemies

NCT02351310

Preterm Labor Premature Birth

WITHDRAWN PHASE3

Tocolytic Therapy for Preterm Labor in Multiple Gestation

NCT02725736

Labor Preterm Multiple

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research question Does tocolysis with atosiban reduce neonatal mortality and mortality in women with threatened preterm birth between 30 and 34 weeks when compared to placebo?

Study design Multicenter, double blinded, placebo controlled RCT

Study population Women with threatened preterm birth between 30 and 34 weeks of gestation are eligible for the trial. More than 20 hospitals (including all 10 perinatal centres) in the Netherlands will participate in this trial, as well as 15 hospitals in the UK and 1 in Dublin, Ireland.

Threatened preterm birth is defined as listed below in the inclusion criteria. Our previous APOSTEL III study showed that half of the women with these criteria deliver within seven days, validating this definition of women at high risk for preterm birth.

Inclusion criteria

* Women ≥ 18 years old
* Singleton or twin pregnancy
* Gestational age between 30 0/7 and 33 6/7 weeks
* Threatened preterm birth defined by regular uterine contractions, AND one of the following:

* Cervical length of \< 15 mm OR
* Cervical length of 15-30 mm and a positive Fibronectine test (≥ 50 ng/mL) OR
* In case of absence of cervical length measurement in local protocol a positive Fibronectin test or Partus test OR
* Ruptured amniotic membranes

Exclusion criteria

* Previous treatment for threatened preterm birth with corticosteroids.
* Contra-indication for tocolysis
* Signs of fetal distress
* Signs of intra uterine infection

Participants RCT: 760 (380 per group)

Description of intervention(s) Tocolysis with atosiban versus placebo.

Outcome measures The primary outcome is a combined perinatal outcome of severe neonatal morbidity and perinatal mortality Secondary outcomes will be birth within 48 hours, time to delivery, gestational age at delivery, birth weight, number of days on invasive mechanical ventilation, length of admission in NICU, convulsions, asphyxia, meningitis, pneumothorax and mortality until 3 months corrected age, maternal infection, maternal side effects and costs.

All outcomes are in the electronic patient file. No additional tests are required for mother or baby.

Power / data analysis Based on the APOSTEL 3 data, the proportion of adverse perinatal outcome in women randomized between 30 and 34 weeks gestation and treated with atosiban was 6%. Based on two recent studies, we expect a 49,8% reduction of 11,95% adverse perinatal outcome in the placebo group to 6% in the atosiban group. Therefore we need to randomize 722 women (beta-error 0.2; alpha error 0.05). Assuming a 5% drop-out rate, we need to randomize 760 women (380 in each arm).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

International, multicenter, double blinded, placebo controlled RCT

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

atosiban

Atosiban: bolus injection of 6.75 mg/0.9 ml atosiban in one minute followed by a continuous infusion of 18 mg/hour (=24ml/hour) for 3 hours followed by a continuous infusion of 6 mg/hour (=8 ml/hour) for the remaining 45 hours.

Group Type EXPERIMENTAL

Atosiban

Intervention Type DRUG

atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.

placebo

Placebo: injection of 0.9 ml saline in one minute followed by a saline infusion for 3 hours (24 ml/hour) followed by a continuous infusion (8 ml/hour) for the remaining 45 hours.

Group Type PLACEBO_COMPARATOR

Atosiban

Intervention Type DRUG

atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atosiban

atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tractocile

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women ≥ 18 years
* Singleton or twin pregnancy
* Gestational age between 30 0/7 and 33 6/7 weeks
* Threatened preterm birth defined by regular uterine contractions, AND one of the following:

* Cervical length of \< 15 mm OR
* Cervical length of 15-30 mm and a positive Fibronectine test (≥ 50 ng/mL) OR
* In case of absence of cervical length measurement in local protocol a positive Fibronectin test or Partus test OR
* Ruptured amniotic membranes

Exclusion Criteria

* Previous treatment for threatened preterm birth with corticosteroids in current pregnancy
* Contra indication for tocolysis
* Signs of fetal distress
* Signs of intra uterine infection

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes